Blinatumomab in Pediatric B-cell Acute Lymphoblastic Leukemia (ALL) With Minimal Residual Disease (MRD)
Clinical trial NCT04604691 · UNKNOWN
Trial details
- NCT number
- NCT04604691
- Sponsor
- Seoul National University Hospital
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-02-18
- Primary completion
- 2023-03-01
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.